Michael Gutch has joined H.I.G. Ventures as a member of its life sciences team. He previously was a venture partner with Lilly Ventures.
H.I.G. Ventures, the venture capital affiliate of H.I.G. Capital, announced today the addition of Michael Gutch, Ph.D. to its life sciences investment team. Michael will work with H.I.G. Managing Directors Aaron Davidson and Bruce Robertson in all stages of the investment process, concentrating on biopharmaceuticals and medical device opportunities.
“We're extremely pleased to welcome Mike to our team,” said Mr. Davidson. “His background complements our investment strategy and his expertise and experience will be a great asset to H.I.G. as well as our life sciences portfolio companies.”
Prior to joining H.I.G., Dr. Gutch was a Principal with Lilly Ventures, the corporate venture capital group of the global pharmaceutical company Eli Lilly and Company in
Prior to Eli Lilly, Dr. Gutch spent time with Genentech and Spring Mill Venture Partners.
Dr. Gutch earned his Ph.D. in Cellular and Molecular Pathology from the State University of New York and was a post-doctoral research fellow at both the
About H.I.G. Ventures
H.I.G. Ventures partners with entrepreneurs to provide the capital, expertise and relationships necessary to build market-leading businesses. With over $550 million in dedicated venture and growth capital under management, the firm's team invests nationally in early to growth-stage information technology, life sciences, healthcare and service businesses. H.I.G. Ventures is the venture capital affiliate of H.I.G. Capital, a leading private equity investment firm with over $4.5 billion of capital under management and offices in